NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TLC stock logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.

TLC Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
See More Headlines
Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/28/2020
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Net Income
$-35,020,000.00
Net Margins
-299.27%
Pretax Margin
-306.10%

Debt

Sales & Book Value

Annual Sales
$3.63 million
Book Value
$0.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Kee Lung Hong
    Chairman & Chief Executive Officer
  • Chih Hung Yeh
    President & General Manager
  • Yi Ju Chen
    Head-Finance & Accounting
  • Yun Lung Tseng
    Deputy General Manager-Research & Development
  • George Spencer-Green
    Chief Medical Officer

TLC Stock Analysis - Frequently Asked Questions

How were Taiwan Liposome's earnings last quarter?

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its earnings results on Wednesday, October, 28th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.28 million for the quarter, compared to the consensus estimate of $0.38 million. Taiwan Liposome had a negative net margin of 299.27% and a negative trailing twelve-month return on equity of 120.45%.

What other stocks do shareholders of Taiwan Liposome own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taiwan Liposome investors own include Gilead Sciences (GILD), Pfizer (PFE), Wells Fargo & Company (WFC), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Celldex Therapeutics (CLDX), Seabridge Gold (SA), Trevena (TRVN), AbbVie (ABBV) and Advanced Micro Devices (AMD).

When did Taiwan Liposome IPO?

Taiwan Liposome (TLC) raised $29 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 5,000,000 shares at a price of $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

This page (NASDAQ:TLC) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners